Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age
- PMID: 26529070
- DOI: 10.1016/j.vaccine.2015.10.097
Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age
Abstract
Background: The safety and tolerability of Flublok(®), a purified recombinant hemagglutinin seasonal influenza vaccine, was compared to AFLURIA(®) in a randomized, blinded clinical trial in adults ≥ 50 years of age with attention to hypersensitivity reactions.
Methods: This blinded, randomized trial of healthy adults ≥ 50 years of age compared safety of Flublok vs. AFLURIA with respect to pre-specified possible hypersensitivity: "rash," "urticaria," "swelling" and "non-dependent edema;" solicited reactogenicity and unsolicited adverse events. Subject-reported outcomes were collected for 30 days after vaccination. All adverse event terms were reviewed by physicians blinded to vaccine group, who added other terms possibly reflecting hypersensitivity. Case records of subjects with possible hypersensitivity were adjudicated by independent experts blinded to treatment assignment to identify likely hypersensitivity reactions. Non-inferiority of the incidence of hypersensitivity in the two vaccine groups was pre-defined as an absolute difference with an upper bound of 2-sided 95% confidence limits ≤ 0.015.
Results: A total of 2640 subjects were enrolled, evenly split in age cohorts of 50-64 and ≥ 65 years. Fifty-two subjects reported at least one term possibly representing hypersensitivity, with a slight imbalance of 31 on Flublok and 21 on AFLURIA. The adjudicators determined that six and four subjects on Flublok and AFLURIA, respectively, likely met clinical criteria for hypersensitivity, yielding a difference in incidence between the two vaccine groups of 0.15% (upper bound of 2-sided 95% CI=0.9%). Reactogenicity and overall adverse event profiles were similar across both vaccines.
Conclusions: Flublok was non-inferior to AFLURIA in adults ≥ 50 years of age with respect to expert-adjudicated events of likely hypersensitivity during 30 days following vaccination (Sponsored by Protein Sciences Corporation; ClinicalTrials.gov number NCT01825200).
Keywords: Allergic reaction; Flublok; Influenza vaccine; Recombinant hemagglutinin vaccine.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27. Vaccine. 2009. PMID: 19716456 Clinical Trial.
-
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.Vaccine. 2013 Nov 12;31(47):5572-8. doi: 10.1016/j.vaccine.2013.08.069. Epub 2013 Sep 7. Vaccine. 2013. PMID: 24016810 Clinical Trial.
-
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.Vaccine. 2011 Oct 13;29(44):7733-9. doi: 10.1016/j.vaccine.2011.07.128. Epub 2011 Aug 9. Vaccine. 2011. PMID: 21835220 Clinical Trial.
-
Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults.Drugs. 2013 Aug;73(12):1357-66. doi: 10.1007/s40265-013-0103-6. Drugs. 2013. PMID: 23928902 Review.
-
Ontology-Based Vaccine Adverse Event Representation and Analysis.Adv Exp Med Biol. 2017;1028:89-103. doi: 10.1007/978-981-10-6041-0_6. Adv Exp Med Biol. 2017. PMID: 29058218 Review.
Cited by
-
Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial.medRxiv [Preprint]. 2024 May 17:2024.05.16.24307455. doi: 10.1101/2024.05.16.24307455. medRxiv. 2024. PMID: 38798684 Free PMC article. Preprint.
-
Design of the Recombinant Influenza Neuraminidase Antigen Is Crucial for Its Biochemical Properties and Protective Efficacy.J Virol. 2021 Nov 23;95(24):e0116021. doi: 10.1128/JVI.01160-21. Epub 2021 Oct 6. J Virol. 2021. PMID: 34613807 Free PMC article.
-
Results of Influenza Vaccination: Short Follow-Up Study of a Turkish Population.Rev Soc Bras Med Trop. 2020 Sep 11;53:e20190605. doi: 10.1590/0037-8682-0605-2019. eCollection 2020. Rev Soc Bras Med Trop. 2020. PMID: 32935776 Free PMC article.
-
Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study.Open Forum Infect Dis. 2020 May 20;7(6):ofaa179. doi: 10.1093/ofid/ofaa179. eCollection 2020 Jun. Open Forum Infect Dis. 2020. PMID: 32617368 Free PMC article.
-
Safety of Inactivated Influenza Vaccine in Patients with Egg Allergy in Kurdistan Province, Iran.Iran J Public Health. 2019 Apr;48(4):758-763. Iran J Public Health. 2019. PMID: 31110987 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous